Experimental new skin cancer treatment shows 70 percent effectiveness.
PLX4032 inhibits BRAF, the driving mutation in more than half of melanomas.
Unlike chemotherapy the drug can be taken orally and has mild side effects.
Larger trials are needed to confirm results and test safety.
